You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtomidate
Accession NumberDB00292  (APRD00965)
TypeSmall Molecule
GroupsApproved
DescriptionImidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]
Structure
Thumb
Synonyms
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
Etomidate
Etomidato
Etomidatum
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amidateinjection, solution2 mg/mLintravenousHospira, Inc.1982-09-07Not applicableUs
Amidateinjection, solution2 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2010-03-10Not applicableUs
Amidateinjection, solution2 mg/mLintravenousHospira, Inc.1982-09-07Not applicableUs
Amidateinjection, solution2 mg/mLintravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Amidateinjection, solution2 mg/mLintravenousHospira, Inc.1982-09-07Not applicableUs
Amidateinjection, solution2 mg/mLintravenousHospira, Inc.1982-09-07Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Etomidateinjection, solution2 mg/mLintravenousCadila Healthcare Limited2015-04-03Not applicableUs
Etomidateinjection2 mg/mLintravenousPfizer Laboratories Div Pfizer Inc.2012-02-03Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousZydus Pharmaceuticals (USA) Inc.2015-04-03Not applicableUs
Etomidateinjection2 mg/mLintravenousHeritage Pharmaceuticals Inc.2012-09-13Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousMylan Institutional LLC2013-04-26Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousAmerican Regent, Inc.2010-06-30Not applicableUs
Etomidateinjection2 mg/mLintravenousWest Ward Pharmaceuticals Corp2016-02-25Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousSagent Pharmaceuticals2012-08-10Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousMylan Institutional LLC2012-02-03Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousAmerican Regent, Inc.2010-06-30Not applicableUs
Etomidateinjection2 mg/mLintravenousWest Ward Pharmaceuticals Corp2016-02-25Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousPharma Force, Inc.2010-06-08Not applicableUs
Etomidateinjection, solution2 mg/mLintravenousMylan Institutional LLC2012-02-03Not applicableUs
Etomidateinjection2 mg/mLintravenousHeritage Pharmaceuticals Inc.2012-09-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
HypnomidateJanssen
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIZ22628B598
CAS number33125-97-2
WeightAverage: 244.289
Monoisotopic: 244.121177766
Chemical FormulaC14H16N2O2
InChI KeyInChIKey=NPUKDXXFDDZOKR-LLVKDONJSA-N
InChI
InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
IUPAC Name
ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate
SMILES
CCOC(=O)C1=CN=CN1[[email protected]](C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-substituted imidazoles. These are heterocyclic compounds containing an imidazole ring substituted at position 1.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentN-substituted imidazoles
Alternative Parents
Substituents
  • Benzenoid
  • N-substituted imidazole
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Carboxylic acid ester
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the induction of general anesthesia.
PharmacodynamicsEtomidate is a non-barbiturate hypnotic that acts at the level of the reticular-activating system to produce anesthesia. Etomidate is an imidazole compound that appears to depress CNS function via GABA. Duration of action is intermediate between thiopental and methohexital, and recovery from a single dose is rapid with little residual depression. Like the barbiturates and propofol, etomidate is does not induce analgesia. Etomidate induces unconsciousness within one circulation time. Recovery is rapid as a result of extensive redistribution and rapid metabolism.
Mechanism of actionEtomidate binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding76%, primarily to serum albumin.
Metabolism

Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites.

Route of eliminationApproximately 75% of the administered dose is excreted in the urine during the first day after injection.
Half life75 minutes.
ClearanceNot Available
ToxicityUndesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.95
Caco-2 permeable+0.6275
P-glycoprotein substrateNon-substrate0.7386
P-glycoprotein inhibitor INon-inhibitor0.8567
P-glycoprotein inhibitor IINon-inhibitor0.8597
Renal organic cation transporterNon-inhibitor0.7918
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.7671
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5432
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8357
Ames testNon AMES toxic0.7989
CarcinogenicityNon-carcinogens0.8795
BiodegradationNot ready biodegradable0.5121
Rat acute toxicity2.5459 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9622
hERG inhibition (predictor II)Non-inhibitor0.8553
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hospira inc
  • Bedford laboratories div ben venue laboratories inc
  • Parenta pharmaceuticals inc
  • Pharmaforce inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous2 mg/mL
Injectionintravenous2 mg/mL
Prices
Unit descriptionCostUnit
Amidate 2 mg/ml vial1.55USD ml
Amidate 2 mg/ml ampul1.19USD ml
Etomidate 2 mg/ml vial1.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142-142.8Godefroi, E.F. and Van Der Eijcken, C.A.M.; U.S. Patent 3,354,173; November 21, 1967; assigned to Janssen Pharrnaceutica NV (Belgium).
water solubility63.2 mg/LNot Available
logP3.05POMONA (1987)
Predicted Properties
PropertyValueSource
Water Solubility0.477 mg/mLALOGPS
logP2.66ALOGPS
logP2.5ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)4.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area44.12 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.59 m3·mol-1ChemAxon
Polarizability26.43 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Douglas E. Raines, “ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS.” U.S. Patent US20130079381, issued March 28, 2013.

US20130079381
General ReferencesNot Available
External Links
ATC CodesN01AX07
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with 7-Nitroindazole.
AcebutololEtomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Etomidate is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Etomidate is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Etomidate is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Alprazolam.
AlprenololEtomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmineptineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Amineptine.
AmisulprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.
AmitriptylineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Etomidate is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amperozide.
AripiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Aripiprazole.
ArotinololEtomidate may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArticaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Asenapine.
AtenololEtomidate may increase the atrioventricular blocking (AV block) activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Azaperone.
AzelastineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etomidate.
BaclofenThe risk or severity of adverse effects can be increased when Etomidate is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.
BefunololEtomidate may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzyl alcohol.
BetaxololEtomidate may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BisoprololEtomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BopindololEtomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
BrimonidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Brotizolam.
BufuralolEtomidate may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Bupivacaine.
BupranololEtomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.
ButacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Etomidate is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Butorphanol.
CarbamazepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Etomidate is combined with Carisoprodol.
CarteololEtomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolEtomidate may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CeliprololEtomidate may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CetirizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clomipramine.
ClomipramineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Etomidate is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clozapine.
CocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Etomidate is combined with Codeine.
CyclizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclobenzaprine.
CyproheptadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Etomidate is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Desflurane.
DesipramineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Etomidate.
DetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.
DextromoramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Etomidate is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Etomidate is combined with Doramectin.
DosulepinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Dosulepin.
DoxepinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
DoxylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Etomidate is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
DroperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Drotebanol.
DuloxetineDuloxetine may decrease the antihypertensive activities of Etomidate.
DyclonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Etomidate is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Etomidate.
EntacaponeThe risk or severity of adverse effects can be increased when Etomidate is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.
EsmirtazapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Esmirtazapine.
EsmololEtomidate may increase the atrioventricular blocking (AV block) activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Eszopiclone.
EthanolEtomidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Etomidate.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.
EthosuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Etizolam.
EtoperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Etomidate is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Etomidate is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Etomidate is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Etomidate is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Etomidate is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Etomidate is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Etomidate is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Etomidate is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydromorphone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
HydroxyzineThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Iloperidone.
ImipramineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.
IndenololEtomidate may increase the atrioventricular blocking (AV block) activities of Indenolol.
IsofluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketobemidone.
LabetalolEtomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Etomidate is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Etomidate is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomilnacipran.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Etomidate.
LevorphanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.
LithiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.
LoxapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Etomidate is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Etomidate is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Etomidate is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Etomidate is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Etomidate is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.
MetoprololEtomidate may increase the atrioventricular blocking (AV block) activities of Metoprolol.
MetyrosineEtomidate may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Etomidate is combined with Milnacipran.
MilnacipranMilnacipran may decrease the antihypertensive activities of Etomidate.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
MirtazapineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mirtazapine.
MolindoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.
NabiloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Nabilone.
NadololEtomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Nalbuphine.
NitrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Etomidate is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Normethadone.
NortriptylineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Etomidate is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Opium.
OrphenadrineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Etomidate.
OsanetantThe risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Paliperidone.
ParaldehydeEtomidate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Etomidate.
ParoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.
PenbutololEtomidate may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Pentobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Etomidate is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pethidine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Pimozide.
PindololEtomidate may increase the atrioventricular blocking (AV block) activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Etomidate is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.
PractololEtomidate may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleEtomidate may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etomidate.
PrilocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Etomidate is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Propoxycaine.
PropranololEtomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.
ProtriptylineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Etomidate is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Etomidate is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.
RisperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Romifidine.
RopiniroleEtomidate may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine.
RotigotineEtomidate may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Etomidate.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Etomidate is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sodium oxybate.
SotalolEtomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.
StiripentolThe risk or severity of adverse effects can be increased when Etomidate is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.
SuvorexantThe risk or severity of adverse effects can be increased when Etomidate is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Etomidate is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.
TetrabenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrodotoxin.
ThalidomideEtomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etomidate.
ThiamylalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiagabine.
TianeptineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Tianeptine.
TiletamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiletamine.
TimololEtomidate may increase the atrioventricular blocking (AV block) activities of Timolol.
TizanidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Etomidate is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Etomidate is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.
TrimipramineThe therapeutic efficacy of Etomidate can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid.
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Etomidate.
VigabatrinThe risk or severity of adverse effects can be increased when Etomidate is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Etomidate is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.
ZolazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Etomidate is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Martin LJ, Oh GH, Orser BA: Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. doi: 10.1097/ALN.0b013e3181bbc961. [PubMed:19809285 ]
  4. Desai R, Ruesch D, Forman SA: Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. Anesthesiology. 2009 Oct;111(4):774-84. doi: 10.1097/ALN.0b013e3181b55fae. [PubMed:19741491 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Creagh O, Torres H, Rodriguez N, Gatica SR: Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate. P R Health Sci J. 2010 Jun;29(2):91-5. [PubMed:20496522 ]
  2. Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L: Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95. [PubMed:14508322 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic transporter activity
Specific Function:
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.
Gene Name:
SLC2A1
Uniprot ID:
P11166
Molecular Weight:
54083.325 Da
References
  1. Stephenson KN, Croxen RL, El-Barbary A, Fenstermacher JD, Haspel HC: Inhibition of glucose transport and direct interactions with type 1 facilitative glucose transporter (GLUT-1) by etomidate, ketamine, and propofol: a comparison with barbiturates. Biochem Pharmacol. 2000 Sep 1;60(5):651-9. [PubMed:10927023 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23